君实生物：2025年上半年净利润亏损4.13亿元

Group 1 - The core viewpoint of the article highlights that Junshi Biosciences reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders of the listed company was 413 million yuan, an improvement from a net loss of 645 million yuan in the same period last year [1] - Research and development expenses accounted for 60.39% of the revenue, which is a decrease of 9.12 percentage points compared to the previous year [1]